Vericel Corp logo

Vericel Corp

VCEL
Healthcare|Biotechnology|USA
$47.00
-1.32 (-2.73%)
DCF (FCF)
$9.33
Tangible Book
$6.88
Graham Number
$8.06
Earnings Power
$1.32

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 332.2, 388.69, 452.73, 522.04, 665.63 ], "ebit_estimate": [ 23.97, 49.64, 84.56, 125.35, 180.96 ], "ebitda_estimate": [ 89.37, 116.4, 151.3, 194.57, null ], "net_income_estimate": [ 24.64, 43.33, 74.61, 103.14, 142.96 ], "per_share_eps_estimate": [ 0.47, 0.88, 1.37, 1.76, 2.26 ], "eps_nri_estimate": [ 0.47, 0.88, 1.37, 1.76, 2.26 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.64, null, null, null, null ], "pretax_income_estimate": [ 28.75, 54.3, 88.56, 117.07, 180.96 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 74.96, 75.64, 76.3, 78, null ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 99.37, 53.65, 34.23, 26.78, 20.8 ], "long_term_growth_rate_mean": 64.63, "long_term_revenue_growth_rate_mean": "17.81", "future_per_share_eps_estimate_growth": 64.63, "future_eps_nri_estimate_growth": 64.63, "future_revenue_estimate_growth": 17.81, "future_ebit_estimate_growth": 98.07, "future_ebitda_estimate_growth": 28.89, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 66.35, "future_pretax_income_estimate_growth": 73.71, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.84, "future_operating_cash_flow_per_share_estimate_growth": null }
quarterly
{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 72.69, 79.47, 111.62, 79.51, 87.52, 90.92, 132.53, 93.75 ], "ebit_estimate": [ -2.82, 3.63, 31.23, -2.93, 4.34, 9.1, 40.35, 1.08 ], "ebitda_estimate": [ 13.2, 18.74, 47.89, 13.22, 20.5, 25.28, 56.44, 17.71 ], "net_income_estimate": [ -1.53, 4.31, 28.14, -1.35, 4.99, 8.87, 34.91, 1.6 ], "per_share_eps_estimate": [ -0.03, 0.08, 0.54, -0.04, 0.11, 0.16, 0.62, 0.02 ], "eps_nri_estimate": [ -0.03, 0.08, 0.54, -0.04, 0.11, 0.16, 0.62, 0.04 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 0.05, 0.08, 0.55, null, null, null, null, null ], "pretax_income_estimate": [ -1.54, 4.89, 32.08, -1.36, 5.94, 10.77, 42.08, 2.01 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 72.96, 73.77, 79, 72.08, 74.05, 75, 79.1, 73 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 84.99, 67.92, 60.8, 54.84, 51.37, null, null, null ], "long_term_growth_rate_mean": 64.63, "long_term_revenue_growth_rate_mean": "17.81", "future_per_share_eps_estimate_growth": 64.63, "future_eps_nri_estimate_growth": 64.63, "future_revenue_estimate_growth": 17.81, "future_ebit_estimate_growth": 98.07, "future_ebitda_estimate_growth": 28.89, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 66.35, "future_pretax_income_estimate_growth": 73.71, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.84, "future_operating_cash_flow_per_share_estimate_growth": null }